376 related articles for article (PubMed ID: 10965496)
1. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
[TBL] [Abstract][Full Text] [Related]
2. Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas.
Tsoli E; Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Kastrinakis NG; Kokotas S; Kanavaros P; Asimacopoulos P; Bramis J; Kletsas D; Papavassiliou AG; Kittas C
Mol Med; 2001 Jun; 7(6):418-29. PubMed ID: 11474135
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
Gorgoulis VG; Zacharatos P; Kotsinas A; Liloglou T; Kyroudi A; Veslemes M; Rassidakis A; Halazonetis TD; Field JK; Kittas C
Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
[TBL] [Abstract][Full Text] [Related]
4. Association of allelic imbalance at locus D13S171 (BRCA2) and p53 alterations with tumor kinetics and chromosomal instability (aneuploidy) in nonsmall cell lung carcinoma.
Gorgoulis VG; Kotsinas A; Zacharatos P; Mariatos G; Liloglou T; Tsoli E; Kokotas S; Fassoulas C; Field JK; Kittas C
Cancer; 2000 Nov; 89(9):1933-45. PubMed ID: 11064350
[TBL] [Abstract][Full Text] [Related]
5. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
[TBL] [Abstract][Full Text] [Related]
6. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C
J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516
[TBL] [Abstract][Full Text] [Related]
7. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas.
Gorgoulis VG; Zacharatos P; Mariatos G; Kotsinas A; Bouda M; Kletsas D; Asimacopoulos PJ; Agnantis N; Kittas C; Papavassiliou AG
J Pathol; 2002 Oct; 198(2):142-56. PubMed ID: 12237873
[TBL] [Abstract][Full Text] [Related]
8. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.
Kinoshita I; Dosaka-Akita H; Mishina T; Akie K; Nishi M; Hiroumi H; Hommura F; Kawakami Y
Cancer Res; 1996 Dec; 56(24):5557-62. PubMed ID: 8971152
[TBL] [Abstract][Full Text] [Related]
9. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
Eymin B; Gazzeri S; Brambilla C; Brambilla E
Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation.
Uchida C; Miwa S; Kitagawa K; Hattori T; Isobe T; Otani S; Oda T; Sugimura H; Kamijo T; Ookawa K; Yasuda H; Kitagawa M
EMBO J; 2005 Jan; 24(1):160-9. PubMed ID: 15577944
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer.
Dworakowska D; Jassem E; Jassem J; Karmoliński A; Lapiński M; Tomaszewski D; Rzyman W; Jaśkiewicz K; Sworczak K; Grossman AB
Lung Cancer; 2009 Oct; 66(1):127-33. PubMed ID: 19200616
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression.
Dworakowska D; Jassem E; Jassem J; Karmoliński A; Dworakowski R; Wirth T; Gruchała M; Rynkiewicz A; Skokowski J; Yla-Herttuala S; Jaśkiewicz K; Czestochowska E
J Cancer Res Clin Oncol; 2005 Sep; 131(9):617-23. PubMed ID: 16028106
[TBL] [Abstract][Full Text] [Related]
13. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
Pinto AE; André S; Laranjeira C; Soares J
Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733
[TBL] [Abstract][Full Text] [Related]
14. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability--evidence of E2F-1 transcriptional control over hCdt1.
Karakaidos P; Taraviras S; Vassiliou LV; Zacharatos P; Kastrinakis NG; Kougiou D; Kouloukoussa M; Nishitani H; Papavassiliou AG; Lygerou Z; Gorgoulis VG
Am J Pathol; 2004 Oct; 165(4):1351-65. PubMed ID: 15466399
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
17. Allelic imbalance at the 5q14 locus is associated with decreased apoptotic rate in non-small cell lung carcinomas (NSCLCs). Possible synergistic effect with p53 gene alterations on apoptosis.
Gorgoulis VG; Mariatos1 G; Manolis EN; Zacharatos P; Kotsinas A; Liloglou T; Vogiatzi T; Tsagkaraki A; Kokotas S; Tsoli E; Alchanatis M; Sfikakis PP; Asimacopoulos PJ; Field JK; Kittas C
Lung Cancer; 2000 Jun; 28(3):211-24. PubMed ID: 10812190
[TBL] [Abstract][Full Text] [Related]
18. A novel p53 mutant retained functional activity in lung carcinomas.
Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
[TBL] [Abstract][Full Text] [Related]
19. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung.
Xue Q; Sano T; Kashiwabara K; Saito M; Oyama T; Nakajima T
Pathol Int; 2002 Feb; 52(2):103-9. PubMed ID: 11940214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
